Fly News Breaks for January 7, 2020
Jan 7, 2020 | 05:19 EDT
Piper Sandler analyst Matt O'Brien downgraded Integra LifeSciences (IART) to Neutral from Overweight with a price target of $58, down from $69. The analyst has concerns about the impact of competition in a couple of Integra's business areas. In addition, he likes "some of the faster growth assets in med tech a little more." NuVasive (NUVA) is O'Brien's favorite name in orthopedics.
News For IART;NUVA From the Last 2 Days
There are no results for your query IART;NUVA